MedTrace Logo

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

NCT02155829 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2021-05-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) veterans who have not had symptom reduction after one or more kinds of medications or therapies.

Conditions

Interventions

DRUG

Riluzole

DRUG

Placebo (for Riluzole)

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • Uniformed Services University of the Health Sciences

    lead FED

Principal Investigators

  • David M Benedek, MD · USUHS, WRNMMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2017-10-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02155829 on ClinicalTrials.gov